CHICAGO, IL, Sibel Health, an award-winning medical technology company, is pleased to announce the closing of $30 million in new equity financing and its 7th FDA 510(k) clearance.
The equity financing was led by Sibel's existing investors, the Steele Foundation for Hope and Dräger, to accelerate commercial deployment of the ANNE® One monitoring platform. The Steele Foundation for Hope previously led Sibel's Series B round, adding an additional $20 million investment. Dräger, an international leader in medical and safety technology, previously led Sibel's Series A round, contributing $10 million more in funding.
Sibel Health is an award-winning medical technology company with a mission to deliver Better Health Data for All®. Based in Chicago with an international office in Seoul, South Korea, Sibel Health is a leading provider of advanced monitoring solutions for patients of all ages in the home or hospital. In addition, Sibel Health offers novel digital health technologies for the pharmaceutical and clinical research markets.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
